Linezolid Accord

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone presented as an intravenous formulation for injection use. It treats serious infections caused by susceptible Gram‑positive bacteria, including skin and soft‑tissue infections and various forms of pneumonia, in adult patients when oral therapy is not suitable.

GNH USA supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibiotic indicated for infections caused by susceptible Gram‑positive organisms. - Skin and soft tissue infections: effective against methicillin‑resistant Staphylococcus aureus and other Gram‑positive pathogens, helping resolve cellulitis and wound infections. - Community‑acquired and nosocomial pneumonia: provides coverage for resistant Streptococcus pneumoniae and Staphylococcus aureus, improving respiratory outcomes. - Complicated Gram‑positive infections: used for bacteremia, endocarditis and osteomyelitis caused by resistant strains, facilitating bacterial eradication.

Linezolid may cause a range of adverse reactions, from mild to severe. Monitoring patients for these events is essential during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be watery. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Metallic taste: altered taste perception. - Thrombocytopenia: reduced platelet count, usually mild.

Serious or Rare Side Effects: - Anemia: significant reduction in red blood cells. - Peripheral neuropathy: nerve pain or sensory changes. - Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance. - Severe hypotension: abrupt drop in blood pressure.

Before initiating Linezolid therapy, clinicians should consider several safety measures. - Monitor blood counts: watch for anemia, thrombocytopenia, or neutropenia. - Assess renal and hepatic function: adjust duration in patients with organ impairment. - Avoid serotonergic drugs: risk of serotonin syndrome with SSRIs, MAO inhibitors, or tramadol. - Caution in myelosuppressed patients: increased risk of hematologic toxicity. - Limit prolonged use: extended therapy may raise the chance of neuropathy. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Linezolid can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Serotonergic agents (SSRIs, SNRIs, MAO inhibitors, tramadol): risk of serotonin syndrome. - Monoamine oxidase inhibitors: additive MAO inhibition may cause hypertensive crisis.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, reducing linezolid plasma levels. - Warfarin: may enhance anticoagulant effect, increasing INR. - NSAIDs: potential additive effect on bleeding risk. - Antacids containing aluminum or magnesium: may affect absorption if given simultaneously. - Ethanol: may increase risk of hypotension when combined with linezolid.